Search research articles
Contact Us
Filters
Showing results (11-20 of 47) with videos related to
Page
of 5
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 29, 2013
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
Ralph Boccia, Steven Grunberg, Edwin Franco-Gonzales, et al.
Pharmacotherapy
|
August 15, 2019
Importance of Initial Complete Parenteral Iron Repletion on Hemoglobin Level Normalization and Health Care Resource Utilization: A Retrospective Analysis
Chris LaVallee, Patrick Cronin, Isha Bansal, et al.
Future Oncology (London, England)
|
August 21, 2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria
Harry Raftopoulos, Ralph Boccia, William Cooper, et al.
Future Oncology (London, England)
|
February 10, 2018
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Jeffrey Vacirca, Dennis Caruana, George Calcanes, et al.
Blood Advances
|
January 26, 2021
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
Shaji Kumar, Alan Fu, Ruben Niesvizky, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 3, 2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
Harry Raftopoulos, William Cooper, Erin O'Boyle, et al.
Cancer Management and Research
|
April 3, 2015
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
Nashat Gabrail, Ronald Yanagihara, Marek Spaczyński, et al.
American Journal of Hematology
|
October 15, 2021
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD)
Tamta Makharadze, Ralph Boccia, Anna Krupa, et al.
American Journal of Hematology
|
August 29, 2013
Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron
Saroj Vadhan-Raj, William Strauss, David Ford, et al.
Journal of Clinical Medicine
|
May 11, 2024
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes
Ralph Boccia, Hong Xiao, Caroline von Wilamowitz-Moellendorff, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 47) with videos related to
Sort By:
Page
of 5
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 29, 2013
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
Ralph Boccia, Steven Grunberg, Edwin Franco-Gonzales, et al.
Pharmacotherapy
|
August 15, 2019
Importance of Initial Complete Parenteral Iron Repletion on Hemoglobin Level Normalization and Health Care Resource Utilization: A Retrospective Analysis
Chris LaVallee, Patrick Cronin, Isha Bansal, et al.
Future Oncology (London, England)
|
August 21, 2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria
Harry Raftopoulos, Ralph Boccia, William Cooper, et al.
Future Oncology (London, England)
|
February 10, 2018
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Jeffrey Vacirca, Dennis Caruana, George Calcanes, et al.
Blood Advances
|
January 26, 2021
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
Shaji Kumar, Alan Fu, Ruben Niesvizky, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 3, 2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
Harry Raftopoulos, William Cooper, Erin O'Boyle, et al.
Cancer Management and Research
|
April 3, 2015
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
Nashat Gabrail, Ronald Yanagihara, Marek Spaczyński, et al.
American Journal of Hematology
|
October 15, 2021
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD)
Tamta Makharadze, Ralph Boccia, Anna Krupa, et al.
American Journal of Hematology
|
August 29, 2013
Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron
Saroj Vadhan-Raj, William Strauss, David Ford, et al.
Journal of Clinical Medicine
|
May 11, 2024
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes
Ralph Boccia, Hong Xiao, Caroline von Wilamowitz-Moellendorff, et al.
Page
of 5